Skip to main content
Springer Nature Link
Log in

Requirements for generic antiepileptic medicines: a clinical perspective

  • Review
  • Published:
Journal of Neurology Aims and scope Submit manuscript

Abstract

Many antiepileptic drugs (AEDs) are now available as a generic product. This can potentially save the healthcare providers massive costs. Hence, governmental authorities have introduced rules and incentives for clinicians to switch from the original branded AED to a generic product. Clinicians and patients with epilepsy are reluctant to switch. The licensing of generic AEDs is based on the equation that bioavailability means therapeutic equivalence. However, from a clinical standpoint one has to consider several other relevant issues: (1) Do generic AEDs have the same efficacy, safety and quality? (2) Can generic AEDs be used as substitutions for brand AEDs? (3) Can generic products of AEDs be used interchangeably? (4) Does the generic AED manufacturer guarantee the long-term consistency of availability on the market? (4) Do generic AEDs reduce the costs, and—if so—are these costs worth any additional risk to patient’s safety? This article reviews the clinical issues related to current bioequivalence, prescribability, and switchability of AEDs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Andermann F, Duh MS, Gosselin A, Paradis PE (2007) Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes. Epilepsia 48:464–469

    Article  PubMed  CAS  Google Scholar 

  2. Anderson S, Hauck WW (1990) Consideration of individual bioequivalence. J Pharmacokinet Biopharm 18:259–273

    Article  PubMed  CAS  Google Scholar 

  3. Andlin-Sobocki P, Jonsson B, Wittchen HU, Olesen J (2005) Cost of disorders of the brain in Europe. Eur J Neurol 12(Suppl 1):1–27

    Article  PubMed  Google Scholar 

  4. Berg MJ (2007) What’s the problem with generic antiepileptic drugs? A call to action. Neurology 68:1245–1246

    Article  PubMed  Google Scholar 

  5. Bialer M (2007) Generic products of antiepileptic drugs (AEDs): is it an issue? Epilepsia 48:1825–1832

    Article  PubMed  Google Scholar 

  6. Bialer M, Midha KK (2010) Generic products of antiepileptic drugs: a perspective on bioequivalence and interchangeability. Epilepsia 51:941–950

    Article  PubMed  CAS  Google Scholar 

  7. Bialer M, Yacobi A, Moros D, Levitt B, Houle JM, Munsaka MS (1998) Criteria to assess in vivo performance and bioequivalence of generic controlled-release formulations of carbamazepine. Epilepsia 39:513–519

    Article  PubMed  CAS  Google Scholar 

  8. Borgheini G (2003) The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs. Clin Ther 25:1578–1592

    Article  PubMed  Google Scholar 

  9. Chen ML (1997) Individual bioequivalence—a regulatory update. J Biopharm Stat 7:5–11

    Article  PubMed  CAS  Google Scholar 

  10. Chen ML, Lesko LJ (2001) Individual bioequivalence revisited. Clin Pharmacokinet 40:701–706

    Article  PubMed  CAS  Google Scholar 

  11. Chen ML, Patnaik R, Hauck WW, Schuirmann DJ, Hyslop T, Williams R (2000) An individual bioequivalence criterion: regulatory considerations. Stat Med 19:2821–2842

    Article  PubMed  CAS  Google Scholar 

  12. Chen ML, Shah V, Patnaik R, Adams W, Hussain A, Conner D, Mehta M, Malinowski H, Lazor J, Huang SM, Hare D, Lesko L, Sporn D, Williams R (2001) Bioavailability and bioequivalence: an FDA regulatory overview. Pharm Res 18:1645–1650

    Article  PubMed  CAS  Google Scholar 

  13. Crawford P, Feely M, Guberman A, Kramer G (2006) Are there potential problems with generic substitution of antiepileptic drugs? A review of issues. Seizure 15:165–176

    Article  PubMed  CAS  Google Scholar 

  14. Davit BM, Conner DP, Fabian-Fritsch B, Haidar SH, Jiang X, Patel DT, Seo PR, Suh K, Thompson CL, Yu LX (2008) Highly variable drugs: observations from bioequivalence data submitted to the FDA for new generic drug applications. AAPS J 10:148–156

    Article  PubMed  CAS  Google Scholar 

  15. Davit BM, Nwakama PE, Buehler GJ, Conner DP, Haidar SH, Patel DT, Yang Y, Yu LX, Woodcock J (2009) Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration. Ann Pharmacother 43:1583–1597

    Article  PubMed  CAS  Google Scholar 

  16. Duh MS, Paradis PE, Latremouille-Viau D, Greenberg PE, Lee SP, Durkin MB, Wan GJ, Rupnow MF, LeLorier J (2009) The risks and costs of multiple-generic substitution of topiramate. Neurology 72:2122–2129

    Article  PubMed  CAS  Google Scholar 

  17. Guberman A, Corman C (2000) Generic substitution for brand name antiepileptic drugs: a survey. Can J Neurol Sci 27:37–43

    PubMed  CAS  Google Scholar 

  18. Haas JS, Phillips KA, Gerstenberger EP, Seger AC (2005) Potential savings from substituting generic drugs for brand-name drugs: medical expenditure panel survey, 1997–2000. Ann Intern Med 142:891–897

    PubMed  Google Scholar 

  19. Haidar SH, Davit B, Chen ML, Conner D, Lee L, Li QH, Lionberger R, Makhlouf F, Patel D, Schuirmann DJ, Yu LX (2008) Bioequivalence approaches for highly variable drugs and drug products. Pharm Res 25:237–241

    Article  PubMed  CAS  Google Scholar 

  20. Haidar SH, Makhlouf F, Schuirmann DJ, Hyslop T, Davit B, Conner D, Yu LX (2008) Evaluation of a scaling approach for the bioequivalence of highly variable drugs. AAPS J 10:450–454

    Article  PubMed  Google Scholar 

  21. Hauck WW, Anderson S (1991) Individual bioequivalence: what matters to the patient. Stat Med 10:959–960

    Article  PubMed  CAS  Google Scholar 

  22. Hauck WW, Anderson S (1992) Types of bioequivalence and related statistical considerations. Int J Clin Pharmacol Ther Toxicol 30:181–187

    PubMed  CAS  Google Scholar 

  23. Hauck WW, Anderson S (1994) Measuring switchability and prescribability: when is average bioequivalence sufficient? J Pharmacokinet Biopharm 22:551–564

    Article  PubMed  CAS  Google Scholar 

  24. Hauck WW, Bois FY, Hyslop T, Gee L, Anderson S (1997) A parametric approach to population bioequivalence. Stat Med 16:441–454

    Article  PubMed  CAS  Google Scholar 

  25. Hauck WW, Hyslop T, Chen ML, Patnaik R, Williams RL (2000) Subject-by-formulation interaction in bioequivalence: conceptual and statistical issues. FDA Population/Individual Bioequivalence Working Group. Food and Drug Administration. Pharm Res 17:375–380

    Article  PubMed  CAS  Google Scholar 

  26. Heaney DC, Sander JW (2007) Antiepileptic drugs: generic versus branded treatments. Lancet Neurol 6:465–468

    Article  PubMed  Google Scholar 

  27. Henney JE (1999) From the Food and Drug Administration. JAMA 282:1995

    Article  PubMed  CAS  Google Scholar 

  28. Kramer G, Biraben A, Carreno M, Guekht A, de Haan GJ, Jedrzejczak J, Josephs D, van RK, Zaccara G (2007) Current approaches to the use of generic antiepileptic drugs. Epilepsy Behav 11:46–52

    Article  PubMed  CAS  Google Scholar 

  29. Kramer G, Denning D, Schmidt D, For the Ad Hoc Kommission der Deutschen Gesellschaft für Neurologie (2005) Generika in der Epileptologie: Was ist zu beachten? Aktuelle Neurologie 32:275–278

    Article  Google Scholar 

  30. LeLorier J, Duh MS, Paradis PE, Lefebvre P, Weiner J, Manjunath R, Sheehy O (2008) Clinical consequences of generic substitution of lamotrigine for patients with epilepsy. Neurology 70:2179–2186

    Article  PubMed  CAS  Google Scholar 

  31. Midha KK, Rawson MJ, Hubbard JW (1997) Individual and average bioequivalence of highly variable drugs and drug products. J Pharm Sci 86:1193–1197

    Article  PubMed  CAS  Google Scholar 

  32. Midha KK, Rawson MJ, Hubbard JW (1998) Bioequivalence: switchability and scaling. Eur J Pharm Sci 6:87–91

    Article  PubMed  CAS  Google Scholar 

  33. Midha KK, Rawson MJ, Hubbard JW (1999) Prescribability and switchability of highly variable drugs and drug products. J Control Release 62:33–40

    Article  PubMed  CAS  Google Scholar 

  34. Nightingale SL, Morrison JC (1987) Generic drugs and the prescribing physician. JAMA 258:1200–1204

    Article  PubMed  CAS  Google Scholar 

  35. Perucca E, Albani F, Capovilla G, Bernardina BD, Michelucci R, Zaccara G (2006) Recommendations of the Italian League against Epilepsy working group on generic products of antiepileptic drugs. Epilepsia 47(Suppl 5):16–20

    Article  PubMed  Google Scholar 

  36. Pugliatti M, Beghi E, Forsgren L, Ekman M, Sobocki P (2007) Estimating the cost of epilepsy in Europe: a review with economic modeling. Epilepsia 48:2224–2233

    PubMed  Google Scholar 

  37. Sander JW (2003) The epidemiology of epilepsy revisited. Curr Opin Neurol 16:165–170

    Article  PubMed  Google Scholar 

  38. Schall R, Luus HG (1992) Comparison of absorption rates in bioequivalence studies of immediate release drug formulations. Int J Clin Pharmacol Ther Toxicol 30:153–159

    PubMed  CAS  Google Scholar 

  39. Schall R, Luus HG (1993) On population and individual bioequivalence. Stat Med 12:1109–1124

    PubMed  CAS  Google Scholar 

  40. Wilner AN (2004) Therapeutic equivalency of generic antiepileptic drugs: results of a survey. Epilepsy Behav 5:995–998

    Article  PubMed  Google Scholar 

  41. Zachry WM III, Doan QD, Clewell JD, Smith BJ (2009) Case-control analysis of ambulance, emergency room, or inpatient hospital events for epilepsy and antiepileptic drug formulation changes. Epilepsia 50:493–500

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

Eugen Trinka has acted as a paid consultant to Eisai, Medtronics, Bial, and UCB. He has received research funding from UCB, biogen-idec, sanofi-aventis, and speakers’ honoraria from Bial, Cyberonics, Desitin Pharma, Eisai, Gerot, Böhringer, Sanofi, Medis, and UCB.

Author information

Authors and Affiliations

  1. Department of Neurology at the Christian Doppler Klinik, Paracelsus Medical University, Salzburg, Ignaz Harrerstrasse 79, 5020, Salzburg, Austria

    Eugen Trinka

  2. Swiss Epiklinik, Zurich, Switzerland

    Günter Krämer

  3. Department of Neurology, Donauspital, Wien, Austria

    Martin Graf

Authors
  1. Eugen Trinka
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. Günter Krämer
    View author publications

    You can also search for this author inPubMed Google Scholar

  3. Martin Graf
    View author publications

    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence to Eugen Trinka.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Trinka, E., Krämer, G. & Graf, M. Requirements for generic antiepileptic medicines: a clinical perspective. J Neurol 258, 2128–2132 (2011). https://doi.org/10.1007/s00415-011-6126-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-011-6126-6

Keywords